Impact of theophylline/corticosteroid combination therapy on sputum hydrogen sulfide levels in patients with COPD

Eur Respir J. 2014 May;43(5):1504-6. doi: 10.1183/09031936.00131513. Epub 2014 Feb 13.

Authors

Paul A Kirkham¹, Matthew Whiteman, Paul G Winyard, Gaetano Caramori, Fabiana Gordon, Paul A Ford, Peter J Barnes, Ian M Adcock, Kian Fan Chung

Affiliation

¹ National Heart and Lung Institute, Imperial College London, London.

PMID: 24525446
DOI: 10.1183/09031936.00131513

No abstract available

Publication types

Randomized Controlled Trial

MeSH terms

Adrenal Cortex Hormones / administration & dosage*
Adrenal Cortex Hormones / therapeutic use
Biomarkers / metabolism
Bronchodilator Agents / therapeutic use
Disease Progression
Forced Expiratory Volume
Glucocorticoids / therapeutic use
Humans
Hydrogen Sulfide / analysis*
Inflammation
Oxidants / chemistry
Pulmonary Disease, Chronic Obstructive / drug therapy*
Pulmonary Disease, Chronic Obstructive / metabolism
Sputum / chemistry*
Theophylline / administration & dosage*
Time Factors
Treatment Outcome

Substances

Adrenal Cortex Hormones
Biomarkers
Bronchodilator Agents
Glucocorticoids
Oxidants
Theophylline
Hydrogen Sulfide

Associated data

ClinicalTrials.gov/NCT00241631